Pulmonary Sarcoidosis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis
Verified date | June 2023 |
Source | aTyr Pharma, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod in participants with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to efzofitimod (N=8) or placebo matched to efzofitimod (N=4).
Status | Completed |
Enrollment | 37 |
Est. completion date | June 29, 2021 |
Est. primary completion date | June 29, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Key Inclusion Criteria: - Diagnosis of pulmonary sarcoidosis for =6 months (cutaneous and ocular involvement allowed), defined as: - Histologically proven diagnosis of sarcoidosis by bronchoscopy, biopsy (any organ) or bronchioalveolar lavage - Parenchymal lung involvement by historical radiological evidence - Must have symptomatic and/or active pulmonary sarcoidosis as evidenced by: - Modified Medical Research Council Dyspnea Scale grade of >= 1; and - Forced vital capacity =50%; and - Receiving treatment with 10 to 25 mg/day of oral prednisone (or equivalent), at a stable dose for =4 weeks prior to Day 1, and capable of undergoing the protocol-specified steroid taper regimen. - Body weight =45 kg and <160 kg. Key Exclusion Criteria: - Current disease presentation consistent with Lofgren's syndrome. - History of severe allergic or anaphylactic reactions to therapeutic proteins or known sensitivity to efzofitimod or to its inactive components (L-histidine, sodium chloride, sucrose, L-methionine, and polysorbate-20). - Treatment with biological immunomodulators such as tumor necrosis factor-alpha inhibitors. - Current evidence of clinically significant cardiovascular, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires other treatment. - Clinically significant pulmonary hypertension requiring vasodilator treatment. - Any history of tuberculosis or evidence of active systemic non-tuberculosis fungal or mycobacterial infection within 1 year of Screening. - History of clinically significant cardiac, neurological, gastrointestinal, and/or renal manifestations of sarcoidosis. - Any condition that necessitated hospitalization within the 3 months prior to Day 1 or is likely to require so during the study. - Participation in another clinical study of an investigational agent or device within 3 months (small molecules) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer. - History of or positive results of screening for hepatitis B, hepatitis C or human immunodeficiency virus. - Is an active, heavy smoker of tobacco/nicotine-containing products (defined as >20 cigarettes/day or e-cigarette equivalent). - Active substance abuse or history of substance abuse within the 12 months prior to Screening. - Participant has received a live vaccination within 8 weeks before Day 1 or inoculation with a live vaccine is planned during study participation. - Positive for Jo-1 antibodies (Ab) at Screening, or past history of Jo-1 Ab positivity. - Significant and/or acute illness within 5 days prior to drug administration that may impact safety assessments, in the opinion of the Investigator. |
Country | Name | City | State |
---|---|---|---|
United States | Emory University | Atlanta | Georgia |
United States | University of Alabama | Birmingham | Alabama |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | aTyr Investigative Site | Chicago | Illinois |
United States | Northwestern University | Chicago | Illinois |
United States | University of Cincinnati | Cincinnati | Ohio |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | UT Southwestern Medical Center | Dallas | Texas |
United States | National Jewish Health | Denver | Colorado |
United States | Inova Fairfax Medical Center | Falls Church | Virginia |
United States | East Carolina University | Greenville | North Carolina |
United States | University of Iowa | Iowa City | Iowa |
United States | University of Louisville | Louisville | Kentucky |
United States | aTyr Investigative Site | Miami | Florida |
United States | aTyr Investigative Site | Northridge | California |
Lead Sponsor | Collaborator |
---|---|
aTyr Pharma, Inc. | Foundation for Sarcoidosis Research |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. TEAEs were defined as any adverse event or worsening of an existing condition after initiation of the investigational product and through 30 days after the participant's last study visit (study completion or early termination). SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. | Baseline up to Week 24 | |
Secondary | Time-adjusted Area Under the Curve (AUC) of Background Oral Corticosteroid (OCS) Usage Over Study Period | Time adjusted AUC is a measure of steroid burden and approximates the average daily OCS dose (mg/day) post-baseline for each participant. Time adjusted AUC was calculated by AUC divided by the number of days between first and last day of time interval of interest. | Baseline up to Week 24 (Day 1 to End of Dosing Period) | |
Secondary | Number of Participants Who Achieved and Maintained The Targeted Tapered Dose of Prednisone 5 mg/Day (or Equivalent) | Baseline up to Week 24 | ||
Secondary | Number of Participants With Positive Anti-Drug Antibodies (Anti-Efzofitimod) | The number of all participants having drug reactive antibodies at any point in time (efzofitimod and placebo matched to efzofitimod) have been reported. | Baseline up to Week 24 | |
Secondary | Number of Participants With at Least One Positive Anti-Jo-1 Antibodies Titers | Baseline up to Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04064242 -
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Terminated |
NCT00262132 -
Mycophenolate for Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT05415137 -
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT00001532 -
Role of Genetic Factors in the Development of Lung Disease
|
||
Completed |
NCT04318392 -
Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
|
||
Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
Completed |
NCT01587001 -
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
|
N/A | |
Recruiting |
NCT05890729 -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT02824419 -
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06205121 -
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
|
Phase 2 | |
Completed |
NCT02200146 -
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
|
Phase 3 | |
Terminated |
NCT01732211 -
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Enrolling by invitation |
NCT06169397 -
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 2 | |
Active, not recruiting |
NCT05368883 -
Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis
|
N/A | |
Not yet recruiting |
NCT05247554 -
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
|
Phase 3 | |
Completed |
NCT03599414 -
CASPA: CArdiac Sarcoidosis in PApworth
|
||
Recruiting |
NCT02188017 -
Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)
|
Phase 4 | |
Recruiting |
NCT06113991 -
Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
|
||
Completed |
NCT01169038 -
Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
|
Phase 1 | |
Completed |
NCT00701207 -
Study of Nicotine Patches in Patients With Sarcoidosis
|
Early Phase 1 |